查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
胃癌全球市場規模/份額/行業趨勢分析報告：按給藥途徑（注射/口服）、治療類型、疾病類型、分銷渠道、藥物類別、地區、展望/預測，2023-2029 年
市場調查報告書
商品編碼
1276338

胃癌全球市場規模/份額/行業趨勢分析報告：按給藥途徑（注射/口服）、治療類型、疾病類型、分銷渠道、藥物類別、地區、展望/預測，2023-2029 年

Global Gastric Cancer Market Size, Share & Industry Trends Analysis Report By Route of Administration (Injectable and Oral), By Treatment Type, By Disease Type, By Distribution Channel, By Drug Class, By Regional Outlook and Forecast, 2023 - 2029
出版日期: | 出版商: KBV Research | 英文 326 Pages | 訂單完成後即時交付

價格

胃癌市場規模預計到 2029 年將達到 69 億美元，預測期內復合年增長率為 17.6%。

由於癌症在不同時間在胃的不同部位發展，因此症狀和預後各不相同。 治療的選擇可能取決於癌症的起源。 例如，在胃食管交界處出現或開始於胃食管交界處的惡性腫瘤的分期和治療通常與食管腫瘤相似。 胃的最內層粘膜含有引起這些惡性腫瘤的腺細胞。

胃腺癌有兩種基本類型：腸型和瀰漫型。 癌細胞更有可能發生某些基因改變，從而更有可能進行靶向藥物治療。 擴散型通常傳播得更快。 與腸型相比，它的發生頻率較低，而且往往難以治療。

COVID-19 影響分析

診斷和治療的延誤是 COVID-19 大流行對胃癌的主要影響。 癌症診斷和治療的延誤會對患者的預後產生重大影響。 癌症研究，尤其是測試胃癌新療法的臨床試驗，也受到大流行的阻礙。 COVID-19 限制已推遲或暫停了許多臨床試驗，可能會延遲針對該疾病的新療法的開發。 然而，在大流行期間，重症病例仍在接受治療。 考慮到這些因素，我們發現胃癌市場受到了 COVID-19 的適度影響。

市場增長因素

擴大靶向治療和免疫治療的接受度，引入新藥

隨著對疾病分子基礎的了解不斷加深，越來越多的靶向和免疫治療藥物被開發並推向市場。 2010年以來，赫賽汀等抗HER-2藥物陸續上市。 目前，EGFR和PD-1靶向治療和免疫治療正在開髮用於治療胃癌。 此外，臨床管道中藥物的批准和後續上市預計將推動胃癌市場的增長。

胃癌患病率上升

胃癌是東亞地區最普遍的癌症類型。 到 2020 年，預計將有 110 萬新發胃癌病例和 77 萬胃癌相關死亡病例，男性患病率通常是女性的兩倍。 在預測期內，由於胃癌患病率的增加，預計胃癌藥物的需求將增加，這有望作為胃癌藥物的市場趨勢引起人們的關注。 在預測期內，這有望幫助胃癌市場增長。

市場製約因素

有限的治療方案及其相關副作用的組合

可以使用化學療法、放射療法或兩者結合手術來治療癌症。 化學療法中使用的藥物通過攻擊快速分裂的癌細胞起作用，但它們也會損害健康細胞，引起令人不快的副作用，例如噁心、嘔吐和疲勞。。 我們預計這將成為未來幾年市場需求的障礙。 此外，治療成本上升和胃癌治療藥物相對有限等因素預計將阻礙預測期內胃癌市場的增長。

按疾病類型劃分的前景

胃癌市場按疾病類型分為腺癌、淋巴瘤、胃腸道間質瘤、類癌等。 在 2022 年的胃癌市場中，淋巴瘤領域佔據了相當大的收入份額。 免疫系統的淋巴細胞是這些腫瘤首先出現的地方。 一些淋巴瘤起源於胃壁，但大多數淋巴瘤起源於身體的其他部位。 根據淋巴瘤的類型和其他變量，這些腫瘤可以得到治療並具有良好的預後。 預計淋巴瘤意識的增強將促進這一領域的擴張。

治療類型的前景

按治療類型劃分，胃癌市場分為免疫療法、靶向療法、化學療法和放射療法/手術療法。 到 2022 年，胃癌市場將由靶向治療領域主導。 在靶向治療中，癌症患者接受專門針對癌細胞中基因或蛋白質的藥物治療。 靶向癌症療法有多種形式，包括激素劑、基因調節劑、血管生成抑製劑、細胞凋亡誘導劑和信號轉導抑製劑。

藥物類別展望

按照藥物類別，胃癌市場分為 PD-1/PD-L1 抑製劑、抗 HER-2 藥物、VEGFR2 抑製劑等。 2022年，PD-1/PD-L1抑製劑板塊將以最大的收入份額主導胃癌市場。 程序性細胞死亡蛋白 1 (PD-1) 和 PD-L1 等免疫檢查點蛋白通常有助於防止可能損害健康組織的過度免疫反應。 許多 PD-1/PD-L1 抑製劑，包括 nivolumab、pembrolizumab 和 atezolizumab，被批准用於治療嚴重或轉移性胃癌。 有幾種藥物已被證明可以延長晚期胃癌患者的生存期並減緩腫瘤生長。

管理路線展望

根據給藥途徑，胃癌市場分為口服藥物和注射藥物。 到 2022 年，注射劑將在胃癌市場佔據最大的收入份額。 由於注射劑直接進入血液，因此它們可能比口服藥物吸收得更快。 它可以幫助需要立即就醫的晚期或轉移性胃癌患者。 隨著更多的藥物到達靶位點，靜脈內給藥也提高了生物利用度。 這可以減少副作用並改善治療結果。

銷售渠道前景

按分銷渠道，胃癌市場分為專業和零售藥店、醫院藥店等。 預計到 2022 年，醫院藥房部門將在胃癌市場中佔據顯著的收入份額。 政府支持的醫院藥房的建立和優惠報銷是醫院藥房部門增長的主要驅動力。 除了這些原因之外，政府還為癌症治療提供了強有力的支持。 此外，由於患者數量增加、胃癌患病率增加以及癌症治療設施數量增加，預計該領域將擴大。

區域展望

按地區劃分，對北美、歐洲、亞太地區和 LAMEA（拉丁美洲、中東和非洲）的胃癌市場進行了分析。 到 2022 年，亞太地區將佔據最大的收入份額，推動胃癌市場的發展。 亞太地區日益老齡化的人口推動了市場擴張。 胃癌診斷的需求是由胃腸道腫瘤和淋巴瘤的流行驅動的。 此外，亞太地區的胃癌患者正在增加，預計這將在預測期內推動亞太地區的市場增長。

合作夥伴關係是市場進入者採取的主要策略。 根據發表在 Cardinal Matrix 上的一項分析，輝瑞公司是胃癌市場的領先先驅。 默克公司、梯瓦製藥工業有限公司、禮來公司是胃癌市場的領先創新者。

內容

第一章市場範圍與研究方法

  • 市場定義
  • 目的
  • 市場範圍
  • 細分
    • 按給藥途徑劃分的全球胃癌市場
    • 按治療類型劃分的全球胃癌市場
    • 按疾病類型劃分的全球胃癌市場
    • 全球胃癌市場（按分銷渠道）
    • 全球胃癌市場：按藥物分類
    • 全球胃癌市場：按地區
  • 調查方法

第 2 章市場概述

  • 簡介
    • 概覽
      • 市場構成和情景
  • 影響市場的主要因素
    • 市場驅動因素
    • 市場製約因素

第 3 章競爭分析 - 世界

  • KBV 基數矩陣
  • 近期的全行業戰略發展
    • 夥伴關係、協作和協議
    • 產品發布和產品擴展
    • 批准和試用
  • 關鍵成功策略
    • 主要閱讀策略

第 4 章全球胃癌市場：按給藥途徑

  • 全球注射藥物市場：按地區
  • 全球口腔市場：按地區

第 5 章全球胃癌市場：按治療類型分類

  • 全球化療市場：按地區
  • 全球靶向治療市場：按地區
  • 全球免疫療法市場：按地區
  • 全球放射治療和手術市場，按地區

第 6 章全球胃癌市場：按疾病類型分類

  • 全球腺癌市場：按地區
  • 全球類癌腫瘤市場：按地區
  • 全球胃腸道間質瘤市場，按地區
  • 全球淋巴瘤市場：按地區
  • 按地區劃分的剩餘全球市場

第 7 章全球胃癌市場：按分銷渠道

  • 全球專業和零售藥店市場，按地區
  • 全球醫院藥房市場：按地區
  • 按地區劃分的剩餘全球市場

第 8 章全球胃癌市場：按藥物類別分類

  • 按地區劃分的全球 PD-1/PD-L1 抑製劑市場
  • 全球抗 HER-2 藥物市場：按地區
  • 全球 VEGFR2 抑製劑市場：按地區
  • 按地區劃分的剩餘全球市場

第 9 章全球胃癌市場：按地區

  • 北美
    • 北美市場：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
      • 其他北美地區
  • 歐洲
    • 歐洲市場：按國家/地區分類
      • 德國
      • 英國
      • 法國
      • 俄羅斯
      • 西班牙
      • 意大利
      • 其他歐洲地區
  • 亞太地區
    • 亞太市場：按國家/地區分類
      • 中國
      • 日本
      • 印度
      • 韓國
      • 新加坡
      • 馬來西亞
      • 其他亞太地區
  • LAMEA（拉丁美洲/中東/非洲）
    • LAMEA 市場：按國家/地區分類
      • 巴西
      • 阿根廷
      • 阿拉伯聯合酋長國
      • 沙特阿拉伯
      • 南非
      • 尼日利亞
      • 拉美其他地區

第10章公司簡介

  • Novartis AG
  • Pfizer, Inc
  • Viatris, Inc（Mylan N.V.）
  • F Hoffmann-La Roche Ltd.
  • Eli Lilly And Company
  • Merck & Co, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Bristol Myers Squibb Company
  • Celltrion Healthcare Co, Ltd.
  • Samsung Biologics Co, Ltd.（Samsung Bioepis Co., Ltd.）

The Global Gastric Cancer Market size is expected to reach $6.9 billion by 2029, rising at a market growth of 17.6% CAGR during the forecast period.

The cells lining the stomach are where gastric cancer, also known as stomach cancer, first develops. Abdominal pain, vomiting, nausea, bloating, and weight loss can all be signs of gastric cancer. Surgery, radiation therapy, chemotherapy, or a combination of these treatments are all possible forms of treatment for gastric cancer.

Cancer develops when the body's cells start to proliferate out of control. Cancerous cells can develop in almost any body portion and spread to other organs. Usually, gastric cancers grow slowly over several decades. Precancerous alterations frequently appear in the inner mucosa of the stomach before genuine cancer develops. Since these early alterations rarely have symptoms, they may go unnoticed.

Different parts of the stomach can develop cancer at different times, which can result in a variety of symptoms and prognoses. Treatment choices may vary depending on the location of the cancer. For instance, malignancies that develop into or begin at the GE junction are often staged and treated similarly to esophageal tumors. The mucosa, the stomach's innermost lining, contains gland cells that give rise to these malignancies.

The intestinal type and diffuse type of stomach adenocarcinomas are the two basic forms. The likelihood of specific gene alterations in cancer cells increases the possibility that they can be treated with targeted medication therapy. The diffuse form typically spreads more rapidly. It is less frequent than the intestinal variety, and it is frequently more challenging to treat.

COVID-19 Impact Analysis

Delays in diagnosis & treatment have been the primary effects of the COVID-19 pandemic on gastric cancer. Delays in cancer diagnosis & treatment were the result, and they can significantly affect how patients turn out. Cancer research, particularly clinical trials looking at novel treatments for gastric cancer, has also been hampered by the pandemic. Due to COVID-19 limits, numerous clinical trials were postponed or suspended, which may be slowing down the creation of new treatments for the illness. However, the severe cases were being treated during the pandemic period. Considering these elements, the gastric cancer market witnessed a moderate impact due to COVID-19.

Market Growth Factors

Growing acceptance of targeted therapy and immunotherapy and introduction of new drugs

The number of targeted medications and immunotherapy treatments being developed and introduced into the market has increased due to a better understanding of the disease's molecular foundation. Since 2010, HER-2-specific medications, such as Herceptin, have been marketed. EGFR and PD-1 targeted therapy and immunotherapies are currently being created to treat gastric cancer. Furthermore, the market for gastric cancer is also anticipated to be driven by the approval and subsequent release of medications in the clinical pipeline aiding the gastric cancer market growth.

Rising Prevalence of Gastric Cancer

Gastric cancer is the most prevalent cancer type in Eastern Asia. 2020 saw an anticipated 1.1 million new cases of stomach cancer and 770 000 gastric cancer-related deaths, with male incidence rates often being twice as high as females. During the forecast period, it is anticipated that the rising prevalence of gastric carcinoma will increase demand for gastric cancer treatments and make them one of the most popular market trends for stomach cancer treatments. During the forecast period, this is expected to help the growth of the gastric cancer market.

Market Restraining Factors

Limited treatment option combined with their associated side effects

Treating cancer using chemotherapy, radiation therapy, or a combination of the two and with surgery is possible. The medications used in chemotherapy function by attacking rapidly dividing cancer cells; however, they can also harm healthy cells, resulting in unpleasant side effects such as nausea, vomiting, and exhaustion. In the next years, it is anticipated that this aspect will function as a barrier to the demand in the market. It is projected that factors such as high therapy costs and relatively limited availability of medications for the treatment of stomach cancer would work together to impede the growth of the gastric cancer market throughout the forecasted period.

Disease Type Outlook

Based on disease type, the gastric cancer market is characterized into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor, and others. The lymphoma segment covered a considerable revenue share in the gastric cancer market in 2022. The immune system's lymphocytes are where these tumors develop in the first place. There are some lymphomas that can begin in the stomach wall, while most lymphomas begin in other areas of the body. Depending on the lymphoma type and other variables, these tumors can be treated and have good prognoses. The rising awareness of the lymphoma are predicted to support the segment's expansion.

Treatment Type Outlook

On the basis of treatment type, the gastric cancer market is classified into immunotherapy, targeted therapy, chemotherapy, and radiation therapy & surgery. The targeted therapy segment acquired a substantial revenue share in the gastric cancer market in 2022. With targeted therapy, cancer patients receive treatment by having pharmaceuticals that specifically target the genes or proteins that the cancer cells have. Targeted therapy for cancer comes in various forms, including hormonal treatments, gene expression regulators, angiogenesis inhibitors, apoptosis inducers, signal transduction inhibitors, and several more.

Drug Class Outlook

By drug class, the gastric cancer market is divided into PD-1/PD-L1 inhibitors, HER2 antagonists, VEGFR2 antagonists, and others. In 2022, the PD-1/PD-L1 inhibitors segment dominated the gastric cancer market with the maximum revenue share. Immune checkpoint proteins such as programmed cell death protein 1 (PD-1) and PD-L1 often aid in preventing overactive immune responses that may harm healthy tissues. For the treatment of severe or metastatic gastric cancer, a number of PD-1/PD-L1 inhibitors, such as nivolumab, pembrolizumab, and atezolizumab, have been licensed. In patients with advanced gastric cancer, several medications have demonstrated effectiveness in extending survival and slowing tumor growth

Route of Administration Outlook

Based on route of administration, the gastric cancer market is segmented into oral and injectable. In 2022, the injectable segment registered the maximum revenue share in the gastric cancer market. Since injectable pharmaceuticals are administered directly into the bloodstream, they can be absorbed faster than oral medicines. This helps individuals with advanced or metastatic stomach cancer, where quick action may be required. More of the drug can reach its target site when it is administered intravenously, which increases bioavailability. Less side effects and better therapeutic outcomes may arise from this.

Distribution Channel Outlook

On the basis of distribution channel, the gastric cancer market is classified into specialty & retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment projected a prominent revenue share in the gastric cancer market in 2022. The creation of government-sponsored hospitals pharmacies as well as advantageous reimbursement are the main causes of the hospital pharmacy segment's growth. These reasons together with the strong support the government has provided for cancer treatment. The segment is also predicted to expand as a result of the growing patient pool, growing prevalence of stomach cancer, and increasing number of cancer treatment facilities.

Regional Outlook

Region wise, the gastric cancer market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region led the gastric cancer market by generating the largest revenue share. The expansion of the market is being driven by the rise in the geriatric population in the Asia-Pacific region. The demand for gastric cancer diagnostics has been driven by the prevalence of gastrointestinal tumors and lymphomas. Furthermore, the rising case of gastric cancer in the region is anticipated to propel the market growth in the Asia Pacific during the projected period.

The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc. is the major forerunner in the Gastric Cancer Market. Companies such as Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company are some of the key innovators in Gastric Cancer Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Pfizer, Inc., Viatris, Inc. (Mylan N.V.), F. Hoffmann-La Roche Ltd., Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd., Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., and Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.).

Strategies deployed in Gastric Cancer Market

Partnerships, Collaborations, and Agreements:

Feb-2023: Pfizer came into collaboration with Tempus, a technology company focused on advancing precision medicine through the practical application of artificial intelligence in healthcare. Following the collaboration, Pfizer would access Tempus' AI-based platform and multimodal data library, together with its clinical trial matching program and companion diagnostic development capabilities.

Jan-2023: Roche signed an agreement with CHEPLAPHARM, following which the latter company took the commercial rights from Roche for Xeloda (capecitabin) in China. Early in 2022, CHEPLAPHARM already had the rights for the extremely potent anti-cancer drug in every country except China and Japan. By incorporating China, CHEPLAPHARM improves its cancer product line and increases its market share in the world's second-largest pharmaceutical market. In 1997, Xeloda® received approval in China for use as a prescription drug. Shanghai Roche Pharmaceuticals got permission from China's State FDA in 2007 to treat advanced gastric cancer, metastatic breast cancer, and colorectal cancer.

Jan-2023: Roche extended its collaboration with CARsgen Therapeutics Holdings Limited, a manufacturer of innovative therapies for the treatment of solid tumors and hematologic malignancies. Following the expansion, the companies aim to evaluate CARsgen's investigational drug AB011, the first humanized monoclonal antibody against Claudin18.2 (CLDN18.2) that received IND clearance across the world, together with atezolizumab, Roche's PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients with gastric or gastroesophageal junction carcinoma. In addition, Roche will be in charge of operating and conducting the research while both businesses would split the costs of the study's AB011 treatment arms.

Marr-2022: Celltrion Healthcare announced that they have got the tender in Brazil, from the Brazilian Federal Government to procure the world's first monoclonal antibody biosimilar Remsima (infliximab). Additionally, the company has won 12 State bids in Brazil to supply Remsima, including the largest state in Brazil Sao Paulo.

Mar-2022: Bristol Myers Squibb announced a clinical collaboration with Transcenta Holding Limited, a clinical-stage biopharmaceutical company, for the evaluation of the combination of TST001, an investigational humanized monoclonal antibody targeting Claudin18.2 created by Transcenta, with Opdivo® (nivolumab), Bristol Myers Squibb's anti-PD-1 therapy. This has been indicated for the treatment of unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJ).

Feb-2022: Bristol Myers Squibb and Ono Pharmaceutical signed an agreement with Prime Research Institute for Medical RWD, Inc. for an industry-sponsored, large-scale, multi-institutional clinical research on gastric cancer patients treated with Opdivo together with chemotherapy. The study would utilize the PRiME-R's "CyberOncology®" data entry support system, which standardizes, organizes, manages, and integrates real-world data in routine cancer clinical practice.

Sep-2021: Roche Diagnostics International came into an agreement with Medical EarlySign, a company focused on developing ML-based decision support tools, for commercializing an AI tool that would detect cancer early. Following the agreement, the companies create the product, clinically validate it, and then market it. The companies would initially concentrate on the field of stomach cancer. EarlySign's software, which includes lab findings, EHR data, and other clinical care, is used in the clinical decision support tool.

Jun-2021: Eli Lilly and Company signed a clinical trial and supply agreement with ALX Oncology, a clinical-stage immuno-oncology company. Following the agreement, the companies aimed to evaluate the combination of Lilly's anti-VEGFR2 antibody, and ALX148, a next-generation CD47 blocker, for the treatment of HER2-positive gastric cancer or gastroesophageal junction cancer patients.

Feb-2021: Novartis Pharma announced a collaboration and license agreement with BeiGene, Ltd., a biotechnology company engaged in the development and commercialization of innovative medicines. The agreement was focused on developing, manufacturing, and commercializing BeiGene's anti-PD-1 antibody tislelizumab in the US, Mexico, Canada, and member countries of the European region, Norway, United Kingdom, Iceland, Switzerland, Russia, Liechtenstein, and Japan. Additionally, both businesses may perform clinical studies around the world to investigate pairings of tislelizumab with other cancer therapies, and BeiGene has the option to co-develop the medicine in North America with Novartis' financial support.

Product Launches and Product Expansions:

Aug-2020: Samsung Bioepis unveiled Ontruzant (trastuzumab), a biosimilar referencing Roche's Herceptin, in Brazil. Ontruzant (150 mg single-dose vials) has been authorized for the treatment of advanced gastric cancer, metastatic HER2-overexpressing breast cancer, and early HER2-overexpressing breast cancer by the Agencia Nacional de Vigilancia Sanitaria (ANVISA), the country's health regulatory body. It was launched in the United States in April 2020.

Mar-2020: Teva Pharmaceuticals USA, Inc., a division of Teva, together with Celltrion Healthcare, announced the availability of HERZUMA®1 (trastuzumab-pkrb) for Injection, a biosimilar to HERCEPTIN®1 in the United States. HERZUMA is approved in combination with cisplatin, capecitabine, or 5-fluorouracil for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not previously undergone treatment for metastatic disease.

Approvals & Trials:

Jun-2022: Eli Lilly and Company and Innovent Biologics, Inc., a biopharmaceutical company, received approval from the National Medical Products Administration (NMPA) of China for the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) together with fluorouracil and platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.

Feb-2022: Samsung Bioepis got approval for ONTRUZANT® (also known as SB3), a biosimilar referencing Herceptin ®i (Trastuzumab) from Health Canada. This biosimilar is used for the treatment of Early Breast Cancer, metastatic gastric cancer (MGC), and Metastatic Breast Cancer (MBC), among adults.

Oct-2021: Bristol Myers Squibb got approval from European Commission for Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy. This biosimilar is utilized for first-line treatment of adult patients with gastroesophageal junction (GEJ), HER2-negative advanced or metastatic gastric, or esophageal adenocarcinoma (EAC) whose tumors express PD-L1 with a combined positive score (CPS) ≥ 5.

Apr-2021: Bristol Myers Squibb received approval from the U.S. Food and Drug Administration (FDA) for Opdivo (nivolumab) (injection for intravenous use), in combination with fluoropyrimidine- and platinum-containing chemotherapy. This biosimilar is utilized for the treatment of patients with gastroesophageal junction cancer, advanced or metastatic gastric cancer, and esophageal adenocarcinoma, regardless of PD-L1 expression status.

Scope of the Study

Market Segments covered in the Report:

By Route of Administration

  • Injectable
  • Oral

By Treatment Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Radiation Therapy & Surgery

By Disease Type

  • Adenocarcinoma
  • Carcinoid Tumor
  • Gastrointestinal Stromal Tumor
  • Lymphoma
  • Others

By Distribution Channel

  • Specialty & Retail Pharmacies
  • Hospital Pharmacies
  • Others

By Drug Class

  • PD-1/PD-L1 Inhibitors
  • HER2 Antagonists
  • VEGFR2 Antagonists
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Novartis AG
  • Pfizer, Inc.
  • Viatris, Inc. (Mylan N.V.)
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly And Company
  • Merck & Co., Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Bristol Myers Squibb Company
  • Celltrion Healthcare Co., Ltd.
  • Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Gastric Cancer Market, by Route of Administration
    • 1.4.2 Global Gastric Cancer Market, by Treatment Type
    • 1.4.3 Global Gastric Cancer Market, by Disease Type
    • 1.4.4 Global Gastric Cancer Market, by Distribution Channel
    • 1.4.5 Global Gastric Cancer Market, by Drug Class
    • 1.4.6 Global Gastric Cancer Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition & Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Approvals & Trials
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)

Chapter 4. Global Gastric Cancer Market by Route of Administration

  • 4.1 Global Injectable Market by Region
  • 4.2 Global Oral Market by Region

Chapter 5. Global Gastric Cancer Market by Treatment Type

  • 5.1 Global Chemotherapy Market by Region
  • 5.2 Global Targeted Therapy Market by Region
  • 5.3 Global Immunotherapy Market by Region
  • 5.4 Global Radiation Therapy & Surgery Market by Region

Chapter 6. Global Gastric Cancer Market by Disease Type

  • 6.1 Global Adenocarcinoma Market by Region
  • 6.2 Global Carcinoid Tumor Market by Region
  • 6.3 Global Gastrointestinal Stromal Tumor Market by Region
  • 6.4 Global Lymphoma Market by Region
  • 6.5 Global Others Market by Region

Chapter 7. Global Gastric Cancer Market by Distribution Channel

  • 7.1 Global Specialty & Retail Pharmacies Market by Region
  • 7.2 Global Hospital Pharmacies Market by Region
  • 7.3 Global Others Market by Region

Chapter 8. Global Gastric Cancer Market by Drug Class

  • 8.1 Global PD-1/PD-L1 Inhibitors Market by Region
  • 8.2 Global HER2 Antagonists Market by Region
  • 8.3 Global VEGFR2 Antagonists Market by Region
  • 8.4 Global Others Market by Region

Chapter 9. Global Gastric Cancer Market by Region

  • 9.1 North America Gastric Cancer Market
    • 9.1.1 North America Gastric Cancer Market by Route of Administration
      • 9.1.1.1 North America Injectable Market by Country
      • 9.1.1.2 North America Oral Market by Country
    • 9.1.2 North America Gastric Cancer Market by Treatment Type
      • 9.1.2.1 North America Chemotherapy Market by Country
      • 9.1.2.2 North America Targeted Therapy Market by Country
      • 9.1.2.3 North America Immunotherapy Market by Country
      • 9.1.2.4 North America Radiation Therapy & Surgery Market by Country
    • 9.1.3 North America Gastric Cancer Market by Disease Type
      • 9.1.3.1 North America Adenocarcinoma Market by Country
      • 9.1.3.2 North America Carcinoid Tumor Market by Country
      • 9.1.3.3 North America Gastrointestinal Stromal Tumor Market by Country
      • 9.1.3.4 North America Lymphoma Market by Country
      • 9.1.3.5 North America Others Market by Country
    • 9.1.4 North America Gastric Cancer Market by Distribution Channel
      • 9.1.4.1 North America Specialty & Retail Pharmacies Market by Country
      • 9.1.4.2 North America Hospital Pharmacies Market by Country
      • 9.1.4.3 North America Others Market by Country
    • 9.1.5 North America Gastric Cancer Market by Drug Class
      • 9.1.5.1 North America PD-1/PD-L1 Inhibitors Market by Country
      • 9.1.5.2 North America HER2 Antagonists Market by Country
      • 9.1.5.3 North America VEGFR2 Antagonists Market by Country
      • 9.1.5.4 North America Others Market by Country
    • 9.1.6 North America Gastric Cancer Market by Country
      • 9.1.6.1 US Gastric Cancer Market
        • 9.1.6.1.1 US Gastric Cancer Market by Route of Administration
        • 9.1.6.1.2 US Gastric Cancer Market by Treatment Type
        • 9.1.6.1.3 US Gastric Cancer Market by Disease Type
        • 9.1.6.1.4 US Gastric Cancer Market by Distribution Channel
        • 9.1.6.1.5 US Gastric Cancer Market by Drug Class
      • 9.1.6.2 Canada Gastric Cancer Market
        • 9.1.6.2.1 Canada Gastric Cancer Market by Route of Administration
        • 9.1.6.2.2 Canada Gastric Cancer Market by Treatment Type
        • 9.1.6.2.3 Canada Gastric Cancer Market by Disease Type
        • 9.1.6.2.4 Canada Gastric Cancer Market by Distribution Channel
        • 9.1.6.2.5 Canada Gastric Cancer Market by Drug Class
      • 9.1.6.3 Mexico Gastric Cancer Market
        • 9.1.6.3.1 Mexico Gastric Cancer Market by Route of Administration
        • 9.1.6.3.2 Mexico Gastric Cancer Market by Treatment Type
        • 9.1.6.3.3 Mexico Gastric Cancer Market by Disease Type
        • 9.1.6.3.4 Mexico Gastric Cancer Market by Distribution Channel
        • 9.1.6.3.5 Mexico Gastric Cancer Market by Drug Class
      • 9.1.6.4 Rest of North America Gastric Cancer Market
        • 9.1.6.4.1 Rest of North America Gastric Cancer Market by Route of Administration
        • 9.1.6.4.2 Rest of North America Gastric Cancer Market by Treatment Type
        • 9.1.6.4.3 Rest of North America Gastric Cancer Market by Disease Type
        • 9.1.6.4.4 Rest of North America Gastric Cancer Market by Distribution Channel
        • 9.1.6.4.5 Rest of North America Gastric Cancer Market by Drug Class
  • 9.2 Europe Gastric Cancer Market
    • 9.2.1 Europe Gastric Cancer Market by Route of Administration
      • 9.2.1.1 Europe Injectable Market by Country
      • 9.2.1.2 Europe Oral Market by Country
    • 9.2.2 Europe Gastric Cancer Market by Treatment Type
      • 9.2.2.1 Europe Chemotherapy Market by Country
      • 9.2.2.2 Europe Targeted Therapy Market by Country
      • 9.2.2.3 Europe Immunotherapy Market by Country
      • 9.2.2.4 Europe Radiation Therapy & Surgery Market by Country
    • 9.2.3 Europe Gastric Cancer Market by Disease Type
      • 9.2.3.1 Europe Adenocarcinoma Market by Country
      • 9.2.3.2 Europe Carcinoid Tumor Market by Country
      • 9.2.3.3 Europe Gastrointestinal Stromal Tumor Market by Country
      • 9.2.3.4 Europe Lymphoma Market by Country
      • 9.2.3.5 Europe Others Market by Country
    • 9.2.4 Europe Gastric Cancer Market by Distribution Channel
      • 9.2.4.1 Europe Specialty & Retail Pharmacies Market by Country
      • 9.2.4.2 Europe Hospital Pharmacies Market by Country
      • 9.2.4.3 Europe Others Market by Country
    • 9.2.5 Europe Gastric Cancer Market by Drug Class
      • 9.2.5.1 Europe PD-1/PD-L1 Inhibitors Market by Country
      • 9.2.5.2 Europe HER2 Antagonists Market by Country
      • 9.2.5.3 Europe VEGFR2 Antagonists Market by Country
      • 9.2.5.4 Europe Others Market by Country
    • 9.2.6 Europe Gastric Cancer Market by Country
      • 9.2.6.1 Germany Gastric Cancer Market
        • 9.2.6.1.1 Germany Gastric Cancer Market by Route of Administration
        • 9.2.6.1.2 Germany Gastric Cancer Market by Treatment Type
        • 9.2.6.1.3 Germany Gastric Cancer Market by Disease Type
        • 9.2.6.1.4 Germany Gastric Cancer Market by Distribution Channel
        • 9.2.6.1.5 Germany Gastric Cancer Market by Drug Class
      • 9.2.6.2 UK Gastric Cancer Market
        • 9.2.6.2.1 UK Gastric Cancer Market by Route of Administration
        • 9.2.6.2.2 UK Gastric Cancer Market by Treatment Type
        • 9.2.6.2.3 UK Gastric Cancer Market by Disease Type
        • 9.2.6.2.4 UK Gastric Cancer Market by Distribution Channel
        • 9.2.6.2.5 UK Gastric Cancer Market by Drug Class
      • 9.2.6.3 France Gastric Cancer Market
        • 9.2.6.3.1 France Gastric Cancer Market by Route of Administration
        • 9.2.6.3.2 France Gastric Cancer Market by Treatment Type
        • 9.2.6.3.3 France Gastric Cancer Market by Disease Type
        • 9.2.6.3.4 France Gastric Cancer Market by Distribution Channel
        • 9.2.6.3.5 France Gastric Cancer Market by Drug Class
      • 9.2.6.4 Russia Gastric Cancer Market
        • 9.2.6.4.1 Russia Gastric Cancer Market by Route of Administration
        • 9.2.6.4.2 Russia Gastric Cancer Market by Treatment Type
        • 9.2.6.4.3 Russia Gastric Cancer Market by Disease Type
        • 9.2.6.4.4 Russia Gastric Cancer Market by Distribution Channel
        • 9.2.6.4.5 Russia Gastric Cancer Market by Drug Class
      • 9.2.6.5 Spain Gastric Cancer Market
        • 9.2.6.5.1 Spain Gastric Cancer Market by Route of Administration
        • 9.2.6.5.2 Spain Gastric Cancer Market by Treatment Type
        • 9.2.6.5.3 Spain Gastric Cancer Market by Disease Type
        • 9.2.6.5.4 Spain Gastric Cancer Market by Distribution Channel
        • 9.2.6.5.5 Spain Gastric Cancer Market by Drug Class
      • 9.2.6.6 Italy Gastric Cancer Market
        • 9.2.6.6.1 Italy Gastric Cancer Market by Route of Administration
        • 9.2.6.6.2 Italy Gastric Cancer Market by Treatment Type
        • 9.2.6.6.3 Italy Gastric Cancer Market by Disease Type
        • 9.2.6.6.4 Italy Gastric Cancer Market by Distribution Channel
        • 9.2.6.6.5 Italy Gastric Cancer Market by Drug Class
      • 9.2.6.7 Rest of Europe Gastric Cancer Market
        • 9.2.6.7.1 Rest of Europe Gastric Cancer Market by Route of Administration
        • 9.2.6.7.2 Rest of Europe Gastric Cancer Market by Treatment Type
        • 9.2.6.7.3 Rest of Europe Gastric Cancer Market by Disease Type
        • 9.2.6.7.4 Rest of Europe Gastric Cancer Market by Distribution Channel
        • 9.2.6.7.5 Rest of Europe Gastric Cancer Market by Drug Class
  • 9.3 Asia Pacific Gastric Cancer Market
    • 9.3.1 Asia Pacific Gastric Cancer Market by Route of Administration
      • 9.3.1.1 Asia Pacific Injectable Market by Country
      • 9.3.1.2 Asia Pacific Oral Market by Country
    • 9.3.2 Asia Pacific Gastric Cancer Market by Treatment Type
      • 9.3.2.1 Asia Pacific Chemotherapy Market by Country
      • 9.3.2.2 Asia Pacific Targeted Therapy Market by Country
      • 9.3.2.3 Asia Pacific Immunotherapy Market by Country
      • 9.3.2.4 Asia Pacific Radiation Therapy & Surgery Market by Country
    • 9.3.3 Asia Pacific Gastric Cancer Market by Disease Type
      • 9.3.3.1 Asia Pacific Adenocarcinoma Market by Country
      • 9.3.3.2 Asia Pacific Carcinoid Tumor Market by Country
      • 9.3.3.3 Asia Pacific Gastrointestinal Stromal Tumor Market by Country
      • 9.3.3.4 Asia Pacific Lymphoma Market by Country
      • 9.3.3.5 Asia Pacific Others Market by Country
    • 9.3.4 Asia Pacific Gastric Cancer Market by Distribution Channel
      • 9.3.4.1 Asia Pacific Specialty & Retail Pharmacies Market by Country
      • 9.3.4.2 Asia Pacific Hospital Pharmacies Market by Country
      • 9.3.4.3 Asia Pacific Others Market by Country
    • 9.3.5 Asia Pacific Gastric Cancer Market by Drug Class
      • 9.3.5.1 Asia Pacific PD-1/PD-L1 Inhibitors Market by Country
      • 9.3.5.2 Asia Pacific HER2 Antagonists Market by Country
      • 9.3.5.3 Asia Pacific VEGFR2 Antagonists Market by Country
      • 9.3.5.4 Asia Pacific Others Market by Country
    • 9.3.6 Asia Pacific Gastric Cancer Market by Country
      • 9.3.6.1 China Gastric Cancer Market
        • 9.3.6.1.1 China Gastric Cancer Market by Route of Administration
        • 9.3.6.1.2 China Gastric Cancer Market by Treatment Type
        • 9.3.6.1.3 China Gastric Cancer Market by Disease Type
        • 9.3.6.1.4 China Gastric Cancer Market by Distribution Channel
        • 9.3.6.1.5 China Gastric Cancer Market by Drug Class
      • 9.3.6.2 Japan Gastric Cancer Market
        • 9.3.6.2.1 Japan Gastric Cancer Market by Route of Administration
        • 9.3.6.2.2 Japan Gastric Cancer Market by Treatment Type
        • 9.3.6.2.3 Japan Gastric Cancer Market by Disease Type
        • 9.3.6.2.4 Japan Gastric Cancer Market by Distribution Channel
        • 9.3.6.2.5 Japan Gastric Cancer Market by Drug Class
      • 9.3.6.3 India Gastric Cancer Market
        • 9.3.6.3.1 India Gastric Cancer Market by Route of Administration
        • 9.3.6.3.2 India Gastric Cancer Market by Treatment Type
        • 9.3.6.3.3 India Gastric Cancer Market by Disease Type
        • 9.3.6.3.4 India Gastric Cancer Market by Distribution Channel
        • 9.3.6.3.5 India Gastric Cancer Market by Drug Class
      • 9.3.6.4 South Korea Gastric Cancer Market
        • 9.3.6.4.1 South Korea Gastric Cancer Market by Route of Administration
        • 9.3.6.4.2 South Korea Gastric Cancer Market by Treatment Type
        • 9.3.6.4.3 South Korea Gastric Cancer Market by Disease Type
        • 9.3.6.4.4 South Korea Gastric Cancer Market by Distribution Channel
        • 9.3.6.4.5 South Korea Gastric Cancer Market by Drug Class
      • 9.3.6.5 Singapore Gastric Cancer Market
        • 9.3.6.5.1 Singapore Gastric Cancer Market by Route of Administration
        • 9.3.6.5.2 Singapore Gastric Cancer Market by Treatment Type
        • 9.3.6.5.3 Singapore Gastric Cancer Market by Disease Type
        • 9.3.6.5.4 Singapore Gastric Cancer Market by Distribution Channel
        • 9.3.6.5.5 Singapore Gastric Cancer Market by Drug Class
      • 9.3.6.6 Malaysia Gastric Cancer Market
        • 9.3.6.6.1 Malaysia Gastric Cancer Market by Route of Administration
        • 9.3.6.6.2 Malaysia Gastric Cancer Market by Treatment Type
        • 9.3.6.6.3 Malaysia Gastric Cancer Market by Disease Type
        • 9.3.6.6.4 Malaysia Gastric Cancer Market by Distribution Channel
        • 9.3.6.6.5 Malaysia Gastric Cancer Market by Drug Class
      • 9.3.6.7 Rest of Asia Pacific Gastric Cancer Market
        • 9.3.6.7.1 Rest of Asia Pacific Gastric Cancer Market by Route of Administration
        • 9.3.6.7.2 Rest of Asia Pacific Gastric Cancer Market by Treatment Type
        • 9.3.6.7.3 Rest of Asia Pacific Gastric Cancer Market by Disease Type
        • 9.3.6.7.4 Rest of Asia Pacific Gastric Cancer Market by Distribution Channel
        • 9.3.6.7.5 Rest of Asia Pacific Gastric Cancer Market by Drug Class
  • 9.4 LAMEA Gastric Cancer Market
    • 9.4.1 LAMEA Gastric Cancer Market by Route of Administration
      • 9.4.1.1 LAMEA Injectable Market by Country
      • 9.4.1.2 LAMEA Oral Market by Country
    • 9.4.2 LAMEA Gastric Cancer Market by Treatment Type
      • 9.4.2.1 LAMEA Chemotherapy Market by Country
      • 9.4.2.2 LAMEA Targeted Therapy Market by Country
      • 9.4.2.3 LAMEA Immunotherapy Market by Country
      • 9.4.2.4 LAMEA Radiation Therapy & Surgery Market by Country
    • 9.4.3 LAMEA Gastric Cancer Market by Disease Type
      • 9.4.3.1 LAMEA Adenocarcinoma Market by Country
      • 9.4.3.2 LAMEA Carcinoid Tumor Market by Country
      • 9.4.3.3 LAMEA Gastrointestinal Stromal Tumor Market by Country
      • 9.4.3.4 LAMEA Lymphoma Market by Country
      • 9.4.3.5 LAMEA Others Market by Country
    • 9.4.4 LAMEA Gastric Cancer Market by Distribution Channel
      • 9.4.4.1 LAMEA Specialty & Retail Pharmacies Market by Country
      • 9.4.4.2 LAMEA Hospital Pharmacies Market by Country
      • 9.4.4.3 LAMEA Others Market by Country
    • 9.4.5 LAMEA Gastric Cancer Market by Drug Class
      • 9.4.5.1 LAMEA PD-1/PD-L1 Inhibitors Market by Country
      • 9.4.5.2 LAMEA HER2 Antagonists Market by Country
      • 9.4.5.3 LAMEA VEGFR2 Antagonists Market by Country
      • 9.4.5.4 LAMEA Others Market by Country
    • 9.4.6 LAMEA Gastric Cancer Market by Country
      • 9.4.6.1 Brazil Gastric Cancer Market
        • 9.4.6.1.1 Brazil Gastric Cancer Market by Route of Administration
        • 9.4.6.1.2 Brazil Gastric Cancer Market by Treatment Type
        • 9.4.6.1.3 Brazil Gastric Cancer Market by Disease Type
        • 9.4.6.1.4 Brazil Gastric Cancer Market by Distribution Channel
        • 9.4.6.1.5 Brazil Gastric Cancer Market by Drug Class
      • 9.4.6.2 Argentina Gastric Cancer Market
        • 9.4.6.2.1 Argentina Gastric Cancer Market by Route of Administration
        • 9.4.6.2.2 Argentina Gastric Cancer Market by Treatment Type
        • 9.4.6.2.3 Argentina Gastric Cancer Market by Disease Type
        • 9.4.6.2.4 Argentina Gastric Cancer Market by Distribution Channel
        • 9.4.6.2.5 Argentina Gastric Cancer Market by Drug Class
      • 9.4.6.3 UAE Gastric Cancer Market
        • 9.4.6.3.1 UAE Gastric Cancer Market by Route of Administration
        • 9.4.6.3.2 UAE Gastric Cancer Market by Treatment Type
        • 9.4.6.3.3 UAE Gastric Cancer Market by Disease Type
        • 9.4.6.3.4 UAE Gastric Cancer Market by Distribution Channel
        • 9.4.6.3.5 UAE Gastric Cancer Market by Drug Class
      • 9.4.6.4 Saudi Arabia Gastric Cancer Market
        • 9.4.6.4.1 Saudi Arabia Gastric Cancer Market by Route of Administration
        • 9.4.6.4.2 Saudi Arabia Gastric Cancer Market by Treatment Type
        • 9.4.6.4.3 Saudi Arabia Gastric Cancer Market by Disease Type
        • 9.4.6.4.4 Saudi Arabia Gastric Cancer Market by Distribution Channel
        • 9.4.6.4.5 Saudi Arabia Gastric Cancer Market by Drug Class
      • 9.4.6.5 South Africa Gastric Cancer Market
        • 9.4.6.5.1 South Africa Gastric Cancer Market by Route of Administration
        • 9.4.6.5.2 South Africa Gastric Cancer Market by Treatment Type
        • 9.4.6.5.3 South Africa Gastric Cancer Market by Disease Type
        • 9.4.6.5.4 South Africa Gastric Cancer Market by Distribution Channel
        • 9.4.6.5.5 South Africa Gastric Cancer Market by Drug Class
      • 9.4.6.6 Nigeria Gastric Cancer Market
        • 9.4.6.6.1 Nigeria Gastric Cancer Market by Route of Administration
        • 9.4.6.6.2 Nigeria Gastric Cancer Market by Treatment Type
        • 9.4.6.6.3 Nigeria Gastric Cancer Market by Disease Type
        • 9.4.6.6.4 Nigeria Gastric Cancer Market by Distribution Channel
        • 9.4.6.6.5 Nigeria Gastric Cancer Market by Drug Class
      • 9.4.6.7 Rest of LAMEA Gastric Cancer Market
        • 9.4.6.7.1 Rest of LAMEA Gastric Cancer Market by Route of Administration
        • 9.4.6.7.2 Rest of LAMEA Gastric Cancer Market by Treatment Type
        • 9.4.6.7.3 Rest of LAMEA Gastric Cancer Market by Disease Type
        • 9.4.6.7.4 Rest of LAMEA Gastric Cancer Market by Distribution Channel
        • 9.4.6.7.5 Rest of LAMEA Gastric Cancer Market by Drug Class

Chapter 10. Company Profiles

  • 10.1 Novartis AG
    • 10.1.1 Company Overview
    • 10.1.2 Financial Analysis
    • 10.1.3 Segmental and Regional Analysis
    • 10.1.4 Research & Development Expense
    • 10.1.5 Recent strategies and developments:
      • 10.1.5.1 Partnerships, Collaborations, and Agreements:
  • 10.2 Pfizer, Inc.
    • 10.2.1 Company Overview
    • 10.2.2 Financial Analysis
    • 10.2.3 Regional & Segmental Analysis
    • 10.2.4 Research & Development Expense
    • 10.2.5 Recent strategies and developments:
      • 10.2.5.1 Partnerships, Collaborations, and Agreements:
  • 10.3 Viatris, Inc. (Mylan N.V.)
    • 10.3.1 Company Overview
    • 10.3.2 Financial Analysis
    • 10.3.3 Segmental Analysis
    • 10.3.4 Research & Development Expense
    • 10.3.5 Recent strategies and developments:
      • 10.3.5.1 Product Launches and Product Expansions:
      • 10.3.5.2 Approvals & Trials:
  • 10.4 F. Hoffmann-La Roche Ltd.
    • 10.4.1 Company Overview
    • 10.4.2 Financial Analysis
    • 10.4.3 Segmental and Regional Analysis
    • 10.4.4 Research & Development Expense
    • 10.4.5 Recent strategies and developments:
      • 10.4.5.1 Partnerships, Collaborations, and Agreements:
      • 10.4.5.2 Product Launches and Product Expansions:
  • 10.5 Eli Lilly And Company
    • 10.5.1 Company Overview
    • 10.5.2 Financial Analysis
    • 10.5.3 Regional Analysis
    • 10.5.4 Research & Development Expenses
    • 10.5.5 Recent strategies and developments:
      • 10.5.5.1 Approvals & Trials:
      • 10.5.5.2 Partnerships, Collaborations, and Agreements:
  • 10.6 Merck & Co., Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Financial Analysis
    • 10.6.3 Segmental and Regional Analysis
    • 10.6.4 Research & Development Expenses
    • 10.6.5 Recent strategies and developments:
      • 10.6.5.1 Partnerships, Collaborations, and Agreements:
  • 10.7 Teva Pharmaceutical Industries Ltd.
    • 10.7.1 Company Overview
    • 10.7.2 Financial Analysis
    • 10.7.3 Regional Analysis
    • 10.7.4 Research & Development Expenses
    • 10.7.5 Recent strategies and developments:
      • 10.7.5.1 Product Launches and Product Expansions:
      • 10.7.5.2 Approvals & Trials:
      • 10.7.5.3 Partnerships, Collaborations, and Agreements:
  • 10.8 Bristol Myers Squibb Company
    • 10.8.1 Company Overview
    • 10.8.2 Financial Analysis
    • 10.8.3 Regional Analysis
    • 10.8.4 Research & Development Expenses
    • 10.8.5 Recent strategies and developments:
      • 10.8.5.1 Partnerships, Collaborations, and Agreements:
      • 10.8.5.2 Approvals & Trials:
  • 10.9 Celltrion Healthcare Co., Ltd.
    • 10.9.1 Company Overview
    • 10.9.2 Financial Analysis
    • 10.9.3 Recent strategies and developments:
      • 10.9.3.1 Partnerships, Collaborations, and Agreements:
  • 10.10. Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)
    • 10.10.1 Company Overview
    • 10.10.2 Financial Analysis
    • 10.10.3 Segmental and Regional Analysis
    • 10.10.4 Research & Development Expenses
    • 10.10.5 Recent strategies and developments:
      • 10.10.5.1 Approvals & Trials:
      • 10.10.5.2 Product Launches and Product Expansions:

LIST OF TABLES

  • TABLE 1 Global Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 2 Global Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Gastric Cancer Market
  • TABLE 4 Product Launches And Product Expansions- Gastric Cancer Market
  • TABLE 5 Approvals & Trials - Gastric Cancer Market
  • TABLE 6 Global Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 7 Global Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 8 Global Injectable Market by Region, 2019 - 2022, USD Million
  • TABLE 9 Global Injectable Market by Region, 2023 - 2029, USD Million
  • TABLE 10 Global Oral Market by Region, 2019 - 2022, USD Million
  • TABLE 11 Global Oral Market by Region, 2023 - 2029, USD Million
  • TABLE 12 Global Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 13 Global Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 14 Global Chemotherapy Market by Region, 2019 - 2022, USD Million
  • TABLE 15 Global Chemotherapy Market by Region, 2023 - 2029, USD Million
  • TABLE 16 Global Targeted Therapy Market by Region, 2019 - 2022, USD Million
  • TABLE 17 Global Targeted Therapy Market by Region, 2023 - 2029, USD Million
  • TABLE 18 Global Immunotherapy Market by Region, 2019 - 2022, USD Million
  • TABLE 19 Global Immunotherapy Market by Region, 2023 - 2029, USD Million
  • TABLE 20 Global Radiation Therapy & Surgery Market by Region, 2019 - 2022, USD Million
  • TABLE 21 Global Radiation Therapy & Surgery Market by Region, 2023 - 2029, USD Million
  • TABLE 22 Global Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 23 Global Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 24 Global Adenocarcinoma Market by Region, 2019 - 2022, USD Million
  • TABLE 25 Global Adenocarcinoma Market by Region, 2023 - 2029, USD Million
  • TABLE 26 Global Carcinoid Tumor Market by Region, 2019 - 2022, USD Million
  • TABLE 27 Global Carcinoid Tumor Market by Region, 2023 - 2029, USD Million
  • TABLE 28 Global Gastrointestinal Stromal Tumor Market by Region, 2019 - 2022, USD Million
  • TABLE 29 Global Gastrointestinal Stromal Tumor Market by Region, 2023 - 2029, USD Million
  • TABLE 30 Global Lymphoma Market by Region, 2019 - 2022, USD Million
  • TABLE 31 Global Lymphoma Market by Region, 2023 - 2029, USD Million
  • TABLE 32 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 33 Global Others Market by Region, 2023 - 2029, USD Million
  • TABLE 34 Global Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 35 Global Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 36 Global Specialty & Retail Pharmacies Market by Region, 2019 - 2022, USD Million
  • TABLE 37 Global Specialty & Retail Pharmacies Market by Region, 2023 - 2029, USD Million
  • TABLE 38 Global Hospital Pharmacies Market by Region, 2019 - 2022, USD Million
  • TABLE 39 Global Hospital Pharmacies Market by Region, 2023 - 2029, USD Million
  • TABLE 40 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 41 Global Others Market by Region, 2023 - 2029, USD Million
  • TABLE 42 Global Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 43 Global Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 44 Global PD-1/PD-L1 Inhibitors Market by Region, 2019 - 2022, USD Million
  • TABLE 45 Global PD-1/PD-L1 Inhibitors Market by Region, 2023 - 2029, USD Million
  • TABLE 46 Global HER2 Antagonists Market by Region, 2019 - 2022, USD Million
  • TABLE 47 Global HER2 Antagonists Market by Region, 2023 - 2029, USD Million
  • TABLE 48 Global VEGFR2 Antagonists Market by Region, 2019 - 2022, USD Million
  • TABLE 49 Global VEGFR2 Antagonists Market by Region, 2023 - 2029, USD Million
  • TABLE 50 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 51 Global Others Market by Region, 2023 - 2029, USD Million
  • TABLE 52 Global Gastric Cancer Market by Region, 2019 - 2022, USD Million
  • TABLE 53 Global Gastric Cancer Market by Region, 2023 - 2029, USD Million
  • TABLE 54 North America Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 55 North America Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 56 North America Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 57 North America Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 58 North America Injectable Market by Country, 2019 - 2022, USD Million
  • TABLE 59 North America Injectable Market by Country, 2023 - 2029, USD Million
  • TABLE 60 North America Oral Market by Country, 2019 - 2022, USD Million
  • TABLE 61 North America Oral Market by Country, 2023 - 2029, USD Million
  • TABLE 62 North America Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 63 North America Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 64 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 65 North America Chemotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 66 North America Targeted Therapy Market by Country, 2019 - 2022, USD Million
  • TABLE 67 North America Targeted Therapy Market by Country, 2023 - 2029, USD Million
  • TABLE 68 North America Immunotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 69 North America Immunotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 70 North America Radiation Therapy & Surgery Market by Country, 2019 - 2022, USD Million
  • TABLE 71 North America Radiation Therapy & Surgery Market by Country, 2023 - 2029, USD Million
  • TABLE 72 North America Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 73 North America Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 74 North America Adenocarcinoma Market by Country, 2019 - 2022, USD Million
  • TABLE 75 North America Adenocarcinoma Market by Country, 2023 - 2029, USD Million
  • TABLE 76 North America Carcinoid Tumor Market by Country, 2019 - 2022, USD Million
  • TABLE 77 North America Carcinoid Tumor Market by Country, 2023 - 2029, USD Million
  • TABLE 78 North America Gastrointestinal Stromal Tumor Market by Country, 2019 - 2022, USD Million
  • TABLE 79 North America Gastrointestinal Stromal Tumor Market by Country, 2023 - 2029, USD Million
  • TABLE 80 North America Lymphoma Market by Country, 2019 - 2022, USD Million
  • TABLE 81 North America Lymphoma Market by Country, 2023 - 2029, USD Million
  • TABLE 82 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 83 North America Others Market by Country, 2023 - 2029, USD Million
  • TABLE 84 North America Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 85 North America Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 86 North America Specialty & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 87 North America Specialty & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 88 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 89 North America Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 90 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 91 North America Others Market by Country, 2023 - 2029, USD Million
  • TABLE 92 North America Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 93 North America Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 94 North America PD-1/PD-L1 Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 95 North America PD-1/PD-L1 Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 96 North America HER2 Antagonists Market by Country, 2019 - 2022, USD Million
  • TABLE 97 North America HER2 Antagonists Market by Country, 2023 - 2029, USD Million
  • TABLE 98 North America VEGFR2 Antagonists Market by Country, 2019 - 2022, USD Million
  • TABLE 99 North America VEGFR2 Antagonists Market by Country, 2023 - 2029, USD Million
  • TABLE 100 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 101 North America Others Market by Country, 2023 - 2029, USD Million
  • TABLE 102 North America Gastric Cancer Market by Country, 2019 - 2022, USD Million
  • TABLE 103 North America Gastric Cancer Market by Country, 2023 - 2029, USD Million
  • TABLE 104 US Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 105 US Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 106 US Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 107 US Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 108 US Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 109 US Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 110 US Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 111 US Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 112 US Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 113 US Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 114 US Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 115 US Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 116 Canada Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 117 Canada Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 118 Canada Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 119 Canada Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 120 Canada Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 121 Canada Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 122 Canada Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 123 Canada Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 124 Canada Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 125 Canada Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 126 Canada Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 127 Canada Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 128 Mexico Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 129 Mexico Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 130 Mexico Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 131 Mexico Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 132 Mexico Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 133 Mexico Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 134 Mexico Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 135 Mexico Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 136 Mexico Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 137 Mexico Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 138 Mexico Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 139 Mexico Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 140 Rest of North America Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 141 Rest of North America Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 142 Rest of North America Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 143 Rest of North America Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 144 Rest of North America Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 145 Rest of North America Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 146 Rest of North America Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 147 Rest of North America Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 148 Rest of North America Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 149 Rest of North America Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 150 Rest of North America Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 151 Rest of North America Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 152 Europe Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 153 Europe Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 154 Europe Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 155 Europe Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 156 Europe Injectable Market by Country, 2019 - 2022, USD Million
  • TABLE 157 Europe Injectable Market by Country, 2023 - 2029, USD Million
  • TABLE 158 Europe Oral Market by Country, 2019 - 2022, USD Million
  • TABLE 159 Europe Oral Market by Country, 2023 - 2029, USD Million
  • TABLE 160 Europe Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 161 Europe Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 162 Europe Chemotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 163 Europe Chemotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 164 Europe Targeted Therapy Market by Country, 2019 - 2022, USD Million
  • TABLE 165 Europe Targeted Therapy Market by Country, 2023 - 2029, USD Million
  • TABLE 166 Europe Immunotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 167 Europe Immunotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 168 Europe Radiation Therapy & Surgery Market by Country, 2019 - 2022, USD Million
  • TABLE 169 Europe Radiation Therapy & Surgery Market by Country, 2023 - 2029, USD Million
  • TABLE 170 Europe Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 171 Europe Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 172 Europe Adenocarcinoma Market by Country, 2019 - 2022, USD Million
  • TABLE 173 Europe Adenocarcinoma Market by Country, 2023 - 2029, USD Million
  • TABLE 174 Europe Carcinoid Tumor Market by Country, 2019 - 2022, USD Million
  • TABLE 175 Europe Carcinoid Tumor Market by Country, 2023 - 2029, USD Million
  • TABLE 176 Europe Gastrointestinal Stromal Tumor Market by Country, 2019 - 2022, USD Million
  • TABLE 177 Europe Gastrointestinal Stromal Tumor Market by Country, 2023 - 2029, USD Million
  • TABLE 178 Europe Lymphoma Market by Country, 2019 - 2022, USD Million
  • TABLE 179 Europe Lymphoma Market by Country, 2023 - 2029, USD Million
  • TABLE 180 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 181 Europe Others Market by Country, 2023 - 2029, USD Million
  • TABLE 182 Europe Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 183 Europe Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 184 Europe Specialty & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 185 Europe Specialty & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 186 Europe Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 187 Europe Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 188 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 189 Europe Others Market by Country, 2023 - 2029, USD Million
  • TABLE 190 Europe Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 191 Europe Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 192 Europe PD-1/PD-L1 Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 193 Europe PD-1/PD-L1 Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 194 Europe HER2 Antagonists Market by Country, 2019 - 2022, USD Million
  • TABLE 195 Europe HER2 Antagonists Market by Country, 2023 - 2029, USD Million
  • TABLE 196 Europe VEGFR2 Antagonists Market by Country, 2019 - 2022, USD Million
  • TABLE 197 Europe VEGFR2 Antagonists Market by Country, 2023 - 2029, USD Million
  • TABLE 198 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 199 Europe Others Market by Country, 2023 - 2029, USD Million
  • TABLE 200 Europe Gastric Cancer Market by Country, 2019 - 2022, USD Million
  • TABLE 201 Europe Gastric Cancer Market by Country, 2023 - 2029, USD Million
  • TABLE 202 Germany Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 203 Germany Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 204 Germany Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 205 Germany Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 206 Germany Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 207 Germany Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 208 Germany Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 209 Germany Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 210 Germany Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 211 Germany Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 212 Germany Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 213 Germany Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 214 UK Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 215 UK Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 216 UK Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 217 UK Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 218 UK Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 219 UK Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 220 UK Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 221 UK Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 222 UK Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 223 UK Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 224 UK Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 225 UK Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 226 France Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 227 France Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 228 France Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 229 France Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 230 France Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 231 France Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 232 France Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 233 France Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 234 France Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 235 France Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 236 France Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 237 France Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 238 Russia Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 239 Russia Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 240 Russia Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 241 Russia Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 242 Russia Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 243 Russia Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 244 Russia Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 245 Russia Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 246 Russia Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 247 Russia Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 248 Russia Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 249 Russia Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 250 Spain Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 251 Spain Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 252 Spain Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 253 Spain Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 254 Spain Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 255 Spain Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 256 Spain Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 257 Spain Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 258 Spain Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 259 Spain Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 260 Spain Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 261 Spain Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 262 Italy Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 263 Italy Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 264 Italy Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 265 Italy Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 266 Italy Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 267 Italy Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 268 Italy Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 269 Italy Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 270 Italy Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 271 Italy Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 272 Italy Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 273 Italy Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 274 Rest of Europe Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 275 Rest of Europe Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 276 Rest of Europe Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 277 Rest of Europe Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 278 Rest of Europe Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 279 Rest of Europe Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 280 Rest of Europe Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 281 Rest of Europe Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 282 Rest of Europe Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 283 Rest of Europe Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 284 Rest of Europe Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 285 Rest of Europe Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 286 Asia Pacific Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 287 Asia Pacific Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 288 Asia Pacific Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 289 Asia Pacific Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 290 Asia Pacific Injectable Market by Country, 2019 - 2022, USD Million
  • TABLE 291 Asia Pacific Injectable Market by Country, 2023 - 2029, USD Million
  • TABLE 292 Asia Pacific Oral Market by Country, 2019 - 2022, USD Million
  • TABLE 293 Asia Pacific Oral Market by Country, 2023 - 2029, USD Million
  • TABLE 294 Asia Pacific Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 295 Asia Pacific Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 296 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 297 Asia Pacific Chemotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 298 Asia Pacific Targeted Therapy Market by Country, 2019 - 2022, USD Million
  • TABLE 299 Asia Pacific Targeted Therapy Market by Country, 2023 - 2029, USD Million
  • TABLE 300 Asia Pacific Immunotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 301 Asia Pacific Immunotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 302 Asia Pacific Radiation Therapy & Surgery Market by Country, 2019 - 2022, USD Million
  • TABLE 303 Asia Pacific Radiation Therapy & Surgery Market by Country, 2023 - 2029, USD Million
  • TABLE 304 Asia Pacific Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 305 Asia Pacific Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 306 Asia Pacific Adenocarcinoma Market by Country, 2019 - 2022, USD Million
  • TABLE 307 Asia Pacific Adenocarcinoma Market by Country, 2023 - 2029, USD Million
  • TABLE 308 Asia Pacific Carcinoid Tumor Market by Country, 2019 - 2022, USD Million
  • TABLE 309 Asia Pacific Carcinoid Tumor Market by Country, 2023 - 2029, USD Million
  • TABLE 310 Asia Pacific Gastrointestinal Stromal Tumor Market by Country, 2019 - 2022, USD Million
  • TABLE 311 Asia Pacific Gastrointestinal Stromal Tumor Market by Country, 2023 - 2029, USD Million
  • TABLE 312 Asia Pacific Lymphoma Market by Country, 2019 - 2022, USD Million
  • TABLE 313 Asia Pacific Lymphoma Market by Country, 2023 - 2029, USD Million
  • TABLE 314 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 315 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
  • TABLE 316 Asia Pacific Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 317 Asia Pacific Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 318 Asia Pacific Specialty & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 319 Asia Pacific Specialty & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 320 Asia Pacific Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 321 Asia Pacific Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 322 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 323 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
  • TABLE 324 Asia Pacific Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 325 Asia Pacific Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 326 Asia Pacific PD-1/PD-L1 Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 327 Asia Pacific PD-1/PD-L1 Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 328 Asia Pacific HER2 Antagonists Market by Country, 2019 - 2022, USD Million
  • TABLE 329 Asia Pacific HER2 Antagonists Market by Country, 2023 - 2029, USD Million
  • TABLE 330 Asia Pacific VEGFR2 Antagonists Market by Country, 2019 - 2022, USD Million
  • TABLE 331 Asia Pacific VEGFR2 Antagonists Market by Country, 2023 - 2029, USD Million
  • TABLE 332 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 333 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
  • TABLE 334 Asia Pacific Gastric Cancer Market by Country, 2019 - 2022, USD Million
  • TABLE 335 Asia Pacific Gastric Cancer Market by Country, 2023 - 2029, USD Million
  • TABLE 336 China Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 337 China Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 338 China Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 339 China Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 340 China Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 341 China Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 342 China Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 343 China Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 344 China Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 345 China Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 346 China Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 347 China Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 348 Japan Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 349 Japan Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 350 Japan Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 351 Japan Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 352 Japan Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 353 Japan Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 354 Japan Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 355 Japan Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 356 Japan Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 357 Japan Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 358 Japan Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 359 Japan Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 360 India Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 361 India Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 362 India Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 363 India Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 364 India Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 365 India Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 366 India Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 367 India Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 368 India Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 369 India Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 370 India Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 371 India Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 372 South Korea Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 373 South Korea Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 374 South Korea Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 375 South Korea Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 376 South Korea Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 377 South Korea Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 378 South Korea Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 379 South Korea Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 380 South Korea Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 381 South Korea Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 382 South Korea Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 383 South Korea Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 384 Singapore Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 385 Singapore Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 386 Singapore Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 387 Singapore Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 388 Singapore Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 389 Singapore Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 390 Singapore Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 391 Singapore Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 392 Singapore Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 393 Singapore Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 394 Singapore Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 395 Singapore Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 396 Malaysia Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 397 Malaysia Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 398 Malaysia Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 399 Malaysia Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 400 Malaysia Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 401 Malaysia Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 402 Malaysia Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 403 Malaysia Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 404 Malaysia Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 405 Malaysia Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 406 Malaysia Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 407 Malaysia Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 408 Rest of Asia Pacific Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 409 Rest of Asia Pacific Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 410 Rest of Asia Pacific Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 411 Rest of Asia Pacific Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 412 Rest of Asia Pacific Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 413 Rest of Asia Pacific Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 414 Rest of Asia Pacific Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 415 Rest of Asia Pacific Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 416 Rest of Asia Pacific Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 417 Rest of Asia Pacific Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 418 Rest of Asia Pacific Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 419 Rest of Asia Pacific Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 420 LAMEA Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 421 LAMEA Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 422 LAMEA Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 423 LAMEA Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 424 LAMEA Injectable Market by Country, 2019 - 2022, USD Million
  • TABLE 425 LAMEA Injectable Market by Country, 2023 - 2029, USD Million
  • TABLE 426 LAMEA Oral Market by Country, 2019 - 2022, USD Million
  • TABLE 427 LAMEA Oral Market by Country, 2023 - 2029, USD Million
  • TABLE 428 LAMEA Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 429 LAMEA Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 430 LAMEA Chemotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 431 LAMEA Chemotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 432 LAMEA Targeted Therapy Market by Country, 2019 - 2022, USD Million
  • TABLE 433 LAMEA Targeted Therapy Market by Country, 2023 - 2029, USD Million
  • TABLE 434 LAMEA Immunotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 435 LAMEA Immunotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 436 LAMEA Radiation Therapy & Surgery Market by Country, 2019 - 2022, USD Million
  • TABLE 437 LAMEA Radiation Therapy & Surgery Market by Country, 2023 - 2029, USD Million
  • TABLE 438 LAMEA Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 439 LAMEA Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 440 LAMEA Adenocarcinoma Market by Country, 2019 - 2022, USD Million
  • TABLE 441 LAMEA Adenocarcinoma Market by Country, 2023 - 2029, USD Million
  • TABLE 442 LAMEA Carcinoid Tumor Market by Country, 2019 - 2022, USD Million
  • TABLE 443 LAMEA Carcinoid Tumor Market by Country, 2023 - 2029, USD Million
  • TABLE 444 LAMEA Gastrointestinal Stromal Tumor Market by Country, 2019 - 2022, USD Million
  • TABLE 445 LAMEA Gastrointestinal Stromal Tumor Market by Country, 2023 - 2029, USD Million
  • TABLE 446 LAMEA Lymphoma Market by Country, 2019 - 2022, USD Million
  • TABLE 447 LAMEA Lymphoma Market by Country, 2023 - 2029, USD Million
  • TABLE 448 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 449 LAMEA Others Market by Country, 2023 - 2029, USD Million
  • TABLE 450 LAMEA Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 451 LAMEA Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 452 LAMEA Specialty & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 453 LAMEA Specialty & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 454 LAMEA Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
  • TABLE 455 LAMEA Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
  • TABLE 456 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 457 LAMEA Others Market by Country, 2023 - 2029, USD Million
  • TABLE 458 LAMEA Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 459 LAMEA Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 460 LAMEA PD-1/PD-L1 Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 461 LAMEA PD-1/PD-L1 Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 462 LAMEA HER2 Antagonists Market by Country, 2019 - 2022, USD Million
  • TABLE 463 LAMEA HER2 Antagonists Market by Country, 2023 - 2029, USD Million
  • TABLE 464 LAMEA VEGFR2 Antagonists Market by Country, 2019 - 2022, USD Million
  • TABLE 465 LAMEA VEGFR2 Antagonists Market by Country, 2023 - 2029, USD Million
  • TABLE 466 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 467 LAMEA Others Market by Country, 2023 - 2029, USD Million
  • TABLE 468 LAMEA Gastric Cancer Market by Country, 2019 - 2022, USD Million
  • TABLE 469 LAMEA Gastric Cancer Market by Country, 2023 - 2029, USD Million
  • TABLE 470 Brazil Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 471 Brazil Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 472 Brazil Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 473 Brazil Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 474 Brazil Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 475 Brazil Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 476 Brazil Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 477 Brazil Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 478 Brazil Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 479 Brazil Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 480 Brazil Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 481 Brazil Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 482 Argentina Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 483 Argentina Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 484 Argentina Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 485 Argentina Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 486 Argentina Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 487 Argentina Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 488 Argentina Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 489 Argentina Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 490 Argentina Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 491 Argentina Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 492 Argentina Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 493 Argentina Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 494 UAE Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 495 UAE Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 496 UAE Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 497 UAE Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 498 UAE Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 499 UAE Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 500 UAE Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 501 UAE Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 502 UAE Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 503 UAE Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 504 UAE Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 505 UAE Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 506 Saudi Arabia Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 507 Saudi Arabia Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 508 Saudi Arabia Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 509 Saudi Arabia Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 510 Saudi Arabia Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 511 Saudi Arabia Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 512 Saudi Arabia Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 513 Saudi Arabia Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 514 Saudi Arabia Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 515 Saudi Arabia Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 516 Saudi Arabia Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 517 Saudi Arabia Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 518 South Africa Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 519 South Africa Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 520 South Africa Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 521 South Africa Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 522 South Africa Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 523 South Africa Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 524 South Africa Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 525 South Africa Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 526 South Africa Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 527 South Africa Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 528 South Africa Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 529 South Africa Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 530 Nigeria Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 531 Nigeria Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 532 Nigeria Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 533 Nigeria Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 534 Nigeria Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 535 Nigeria Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 536 Nigeria Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 537 Nigeria Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 538 Nigeria Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 539 Nigeria Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 540 Nigeria Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 541 Nigeria Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 542 Rest of LAMEA Gastric Cancer Market, 2019 - 2022, USD Million
  • TABLE 543 Rest of LAMEA Gastric Cancer Market, 2023 - 2029, USD Million
  • TABLE 544 Rest of LAMEA Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
  • TABLE 545 Rest of LAMEA Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
  • TABLE 546 Rest of LAMEA Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
  • TABLE 547 Rest of LAMEA Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
  • TABLE 548 Rest of LAMEA Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 549 Rest of LAMEA Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 550 Rest of LAMEA Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
  • TABLE 551 Rest of LAMEA Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
  • TABLE 552 Rest of LAMEA Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
  • TABLE 553 Rest of LAMEA Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
  • TABLE 554 Key Information - Novartis AG
  • TABLE 555 Key Information - Pfizer, Inc.
  • TABLE 556 key information - Viatris, Inc.
  • TABLE 557 KEY INFORMATION - F. Hoffmann-La Roche Ltd.
  • TABLE 558 Key Information - Eli Lilly And Company
  • TABLE 559 KEY INFORMATION - Merck & Co., Inc.
  • TABLE 560 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 561 Key Information - Bristol Myers Squibb Company
  • TABLE 562 Key Information - Celltrion Healthcare Co., Ltd.
  • TABLE 563 Key Information - Samsung Biologics Co., Ltd.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 KBV Cardinal Matrix
  • FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
  • FIG 4 Global Gastric Cancer Market share by Route of Administration, 2022
  • FIG 5 Global Gastric Cancer Market share by Route of Administration, 2029
  • FIG 6 Global Gastric Cancer Market by Route of Administration, 2019 - 2029, USD Million
  • FIG 7 Global Gastric Cancer Market share by Treatment Type, 2022
  • FIG 8 Global Gastric Cancer Market share by Treatment Type, 2029
  • FIG 9 Global Gastric Cancer Market by Treatment Type, 2019 - 2029, USD Million
  • FIG 10 Global Gastric Cancer Market share by Disease Type, 2022
  • FIG 11 Global Gastric Cancer Market share by Disease Type, 2029
  • FIG 12 Global Gastric Cancer Market by Disease Type, 2019 - 2029, USD Million
  • FIG 13 Global Gastric Cancer Market share by Distribution Channel, 2022
  • FIG 14 Global Gastric Cancer Market share by Distribution Channel, 2029
  • FIG 15 Global Gastric Cancer Market by Distribution Channel, 2019 - 2029, USD Million
  • FIG 16 Global Gastric Cancer Market share by Drug Class, 2022
  • FIG 17 Global Gastric Cancer Market share by Drug Class, 2029
  • FIG 18 Global Gastric Cancer Market by Drug Class, 2019 - 2029, USD Million
  • FIG 19 Global Gastric Cancer Market share by Region, 2022
  • FIG 20 Global Gastric Cancer Market share by Region, 2029
  • FIG 21 Global Gastric Cancer Market by Region, 2019 - 2029, USD Million
  • FIG 22 Recent strategies and developments: Viatris, Inc.
  • FIG 23 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
  • FIG 24 Recent strategies and developments: Teva Pharmaceuticals Industries Ltd.
  • FIG 25 Recent strategies and developments: Samsung Biologics Co., Ltd.